Erythromycin degradation by an esterase in enzymatic membrane reactors

1 Introduction Pharmaceuticals products (PPs) and endocrine disrupting chemicals (EDCs) as well as their transformation products have been detected in almost all effluents from sewage facilities, in surface water, in groundwater, adsorbed on sediments and even in drinking water [1,2]. Ecotoxicity studies have demonstrated that pharmaceutical pollutants could affect the growth, reproduction and behavior of birds, fishes, invertebrates, plants and bacteria [3,4]. Some recently published studies report that the presence of low concentrations of antibiotics in the wastewaters may develop antibiotic resistance in the whole environment [5, 6]. As previously reported by Demarche et al. [7], the use of enzymes might be beneficial to enhance or complement conventional wastewater treatments. As far as enzymes are relatively expensive the reuse of the biocatalyst appears to be essential to ensure the economic and industrial viability of the process. Enzymatic membrane reactors appear to be an interesting alternative since they enable to couple reaction and separation [8]. In fact, in such enzymatic reactors, the substrate is continuously brought in contact with the biocatalyst, which is retained by the membrane, either freely circulating with the retentate or fixed on or within the membrane and the reaction products are recovered in the permeate. This work describes the study of erythromycin degradation by an EreB esterase in free and immobilized forms. It focuses on the comparison between 3 different enzymatic membrane reactors for erythromycin degradation by esterase EreB. In the first configuration the free biocatalyst was confined in the reaction media by a ceramic membrane. In the two other cases, the enzyme was immobilized in the membrane either covalently grafted or adsorbed. Please click Additional Files below to see the full abstract

Design and optimisation of enzymatic bioreactors for removal of recalcitrant pharmaceutical products from water

Les micropolluants d'origine pharmaceutique tels que les antibiotiques, les hormones, les anti-inflammatoires ou les médicaments anticancéreux sont généralement réfractaires aux procédés classiques de traitement des eaux et leur rejet dans l'environnement même à l'état de traces (< µg/L) pose de réels problèmes environnementaux et de santé publique. Le traitement de ces effluents par voie enzymatique semble être une alternative intéressante et ce d'autant plus si le biocatalyseur est immobilisé directement à la surface d'une membrane afin d'améliorer sa stabilité et permettre sa réutilisation. Le travail à réaliser dans le cadre de cette thèse vise la conception et l'optimisation de bioréacteurs destinés à la dégradation de micropolluants ciblés. Réalisé dans le cadre d'un contrat Européen (ENDETECH), ce travail est une collaboration avec d'autres équipes de recherche européennes en charge de sélectionner les biocatalyseurs et de mettre au point les méthodes analytiques de détection et de caractérisation des produits de la réaction.Pharmaceutical micropollutants such as antibiotics, hormones, anti-inflammatory or anti-cancer drugs are usually reluctant to conventional wastewater treatment processes and their disposal in the environment, even at low concentrations (< µg/L) may have an impact on human health. The enzymatic treatment of these effluents seems a promising alternative if the biocatalyst is immobilized on a membrane to enhance its stability and to enable its reuse. This thesis work aims at designing and optimizing bioreactors for micropollutants degradation. It is a collaboration (ENDETECH project) with other European research teams in charge of selecting the biocatalysts and developing analytical methods for the detection and characterization of transformation products

Membrane Bioprocesses for Pharmaceutical Micropollutant Removal from Waters

The purpose of this review work is to give an overview of the research reported on bioprocesses for the treatment of domestic or industrial wastewaters (WW) containing pharmaceuticals. Conventional WW treatment technologies are not efficient enough to completely remove all pharmaceuticals from water. Indeed, these compounds are becoming an actual public health problem, because they are more and more present in underground and even in potable waters. Different types of bioprocesses are described in this work: from classical activated sludge systems, which allow the depletion of pharmaceuticals by bio-degradation and adsorption, to enzymatic reactions, which are more focused on the treatment of WW containing a relatively high content of pharmaceuticals and less organic carbon pollution than classical WW. Different aspects concerning the advantages of membrane bioreactors for pharmaceuticals removal are discussed, as well as the more recent studies on enzymatic membrane reactors to the depletion of these recalcitrant compounds

Removal of antibiotics in wastewater by enzymatic treatment with fungal laccase – Degradation of compounds does not always eliminate toxicity

International audienc

Removal of Endocrine Disrupting Chemicals in Wastewater by Enzymatic Treatment with Fungal Laccases

In this study the enzymatic degradation of hormones and endocrine disrupting compounds (EDCs) was investigated in artificial mixtures and in real wastewater by fungal laccases (<i>Trametes versicolor, Myceliophthora thermophila</i>). Several studies have already reported the successful enzymatic degradation of EDCs. However, with regards to a large-scale application, the influence of some factors such as enzyme immobilization and costs are often lacking. Furthermore, the majority of studies investigated the removal of EDCs by chemical analysis only, while our main interest was to use bioassays to study the decrease in the endocrine activity. The removal of estrogenic, androgenic, and antiandrogenic activity was assessed by yeast-based reporter gene assays and the degradation of industrial chemicals by an additional chemical analysis. It was demonstrated that the degradation of hormones and EDCs by laccases is feasible even at very low enzyme concentrations (2.8 ABTS U/L). In the artificial mixtures the main removal mechanism was adsorption onto immobilization supports. In binary mixtures, immobilized laccase was best in removing EDCs within the first 6 h of exposure (83% for <i>T. versicolor</i> and 87% for <i>M. thermophila</i>), but in the course of the experiment adsorption superimposed this removal after 24 h (99% after 24 h). A similar pattern was seen in wastewater, but with less carrier material (lower adsorption) and a constant enzyme activity, immobilized laccase showed the best removal rates of estrogenic (82% removal after 24 h) and androgenic activity (99% removal after 6 h). With this in mind, this enzymatic technology can be a valuable addition to other treatment technologies

LUMINEU: a search for neutrinoless double beta decay based on ZnMoO 4 scintillating bolometers

The LUMINEU is designed to investigate the possibility to search for neutrinoless double beta decay in 100Mo by means of a large array of scintillating bolometers based on ZnMoO4 crystals enriched in 100Mo. High energy resolution and relatively fast detectors, which are able to measure both the light and the heat generated upon the interaction of a particle in a crystal, are very promising for the recognition and rejection of background events. We present the LUMINEU concepts and the experimental results achieved aboveground and underground with large-mass natural and enriched crystals. The measured energy resolution, the α/β discrimination power and the radioactive internal contamination are all within the specifications for the projected final LUMINEU sensitivity. Simulations and preliminary results confirm that the LUMINEU technology can reach zero background in the region of interest (around 3 MeV) with exposures of the order of hundreds kgXyears, setting the bases for a next generation 0v2β decay experiment capable to explore the inverted hierarchy region of the neutrino mass pattern